In an interview with PharmaShots, Dr. Andrew Krivoshik, Senior Vice President and Oncology Therapeutic Area Head at Astellas, shared his views on the P-II FAST study result published in the journal Gastric Cancer and highlights the data published in Annals of Oncology.
Shots:
The data from P-II FAST study evaluating zolbetuximab + EOX in 1L patients with advanced gastric and…
